Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study

Objectives Although rapid screening and treatment programmes have been recently implemented to tackle STIs, testing Mycoplasma genitalium (MG) among asymptomatic populations is not currently recommended due to the lack of scientific evidence and the emergence of antibiotic resistance. The main objective of this study was to estimate the prevalence of MG and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening and to identify risk factors associated with the acquisition of this infection. Methods Between October 2017 and January 2018, a total of 890 asymptomatic individuals attending to the STI screening service Drassanes Exprés in Barcelona, Spain, were tested for MG and macrolide resistance using the molecular ResistancePlus MG assay (SpeeDx, Australia). Asymptomatically infected individuals were invited to attend the STI Unit for resistance-guided antimicrobial therapy. Results Overall, the prevalence of MG was 7.4% (66/890; 95% CI 5.8% to 9.3%), being higher among men who have sex with men (MSM) (46/489) compared with heterosexual men and women (20/401; p=0.012). Macrolide resistance was found in 32/46 (69.6%; 95% CI 54.2% to 82.3%) MSM, while only 2/20 (10.0%; 95% CI 1.2% to 31.7%) infections among heterosexuals presented macrolide resistance-mediated mutations (p<0.001). MSM behaviour, receptive anal intercourse, HIV positive status, syphilis history and high-risk sexual activity (more than five sexual partners in the last 3 months) were significantly associated with MG infection. Furthermore, the resistance-guided therapy approach was implemented in 36/66 (54.6%) individuals. Conclusions The research provides further data regarding the prevalence of MG and macrolide resistance among asymptomatic individuals. It also identifies higher risk subpopulations which might be targets for MG screening. Nevertheless, there is insufficient data to justify MG testing among asymptomatic individuals and current STI guidelines should be followed until evidence shows the cost and effectiveness of screening.

[1]  S. Garland,et al.  Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  N. Hens,et al.  Is Screening for Chlamydia and Gonorrhea in Men Who Have Sex With Men Associated With Reduction of the Prevalence of these Infections? A Systematic Review of Observational Studies , 2018, Sexually transmitted diseases.

[3]  S. Philip,et al.  A Silent Epidemic: The Prevalence, Incidence and Persistence of Mycoplasma genitalium Among Young, Asymptomatic High-Risk Women in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P. White,et al.  Syndromic management of STIs and the threat of untreatable Mycoplasma genitalium. , 2018, The Lancet. Infectious diseases.

[5]  N. Low,et al.  Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis , 2017, Sexually Transmitted Infections.

[6]  C. Mercer,et al.  Should we screen for the sexually-transmitted infection Mycoplasma genitalium? Evidence synthesis using a transmission-dynamic model , 2017, Scientific Reports.

[7]  J. Ong,et al.  Mycoplasma genitalium Infection in Adults Reporting Sexual Contact with Infected Partners, Australia, 2008–2016 , 2017, Emerging infectious diseases.

[8]  J. Jensen,et al.  Mycoplasma genitalium Macrolide and Fluoroquinolone Resistance: Prevalence and Risk Factors Among a 2013–2014 Cohort of Patients in Barcelona, Spain , 2017, Sexually transmitted diseases.

[9]  M. Golden,et al.  Developing a Public Health Response to Mycoplasma genitalium , 2017, The Journal of infectious diseases.

[10]  M. Unemo,et al.  Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium , 2017, Nature Reviews Urology.

[11]  M. Cusini,et al.  Background review for the 2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  M. Cusini,et al.  2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology.

[13]  D. Getman,et al.  Mycoplasma genitalium Prevalence, Coinfection, and Macrolide Antibiotic Resistance Frequency in a Multicenter Clinical Study Cohort in the United States , 2016, Journal of Clinical Microbiology.

[14]  S. Garland,et al.  Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology , 2016, PloS one.

[15]  C. Burnham,et al.  The ABCs of STIs: An Update on Sexually Transmitted Infections. , 2016, Clinical chemistry.

[16]  Sebastian Bonhoeffer,et al.  Antibiotic-Resistant Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners , 2016, PLoS pathogens.

[17]  M. Unemo,et al.  2015 European guideline on the management of Chlamydia trachomatis infections , 2010, International journal of STD & AIDS.

[18]  Anne M Johnson,et al.  Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) , 2015, International journal of epidemiology.

[19]  J. Hocking,et al.  The Efficacy of Azithromycin for the Treatment of Genital Mycoplasma genitalium: A Systematic Review and Meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Yasuda,et al.  Drug Resistance – Associated Mutations in Mycoplasma genitalium in Female Sex Workers , 2019 .

[21]  A. Rowhani-Rahbar,et al.  Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Xiangsheng Chen,et al.  The prevalence of urethral and rectal Mycoplasma genitalium among men who have sex with men in China, a cross-sectional study , 2014, BMC Public Health.

[23]  Navneet R. Hakhu,et al.  Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Unemo,et al.  2012 European guideline on the diagnosis and treatment of gonorrhoea in adults , 2013, International journal of STD & AIDS.

[25]  D. Taylor-Robinson,et al.  Mycoplasma genitalium: from Chrysalis to Multicolored Butterfly , 2011, Clinical Microbiology Reviews.

[26]  M. Yasuda,et al.  Selection of Mycoplasma genitalium strains harbouring macrolide resistance-associated 23S rRNA mutations by treatment with a single 1 g dose of azithromycin , 2011, Sexually Transmitted Infections.

[27]  M. Unemo,et al.  European Guideline for the Management of Chlamydia Trachomatis Infections , 2022 .

[28]  L. Manhart.  Has the time come to systematically test for Mycoplasma genitalium? , 2009, Sexually transmitted diseases.

[29]  T. Mroczkowski,et al.  A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  H. Weiss,et al.  Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis , 2009, AIDS.

[31]  S. Tabrizi,et al.  Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.